Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGF MDI HFO vs HFA Propellant in COPD
NCT06075095Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2024
- Primary completion
- Aug 2025
- Modality
- Orthosteric Ligands
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of EPI-EE, glycopyrronium and formoterol in chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by AstraZeneca. Primary endpoints: Area Under the Curve for Forced Expiratory Volume in 1 Second from 0 to 4 hours and Morning Pre-dose Trough Forced Expiratory Volume in 1 Second at Day 29. Started Jan 2024; status: completed.
02
Drugs
EPI-EEglycopyrroniumformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06075095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06075095.